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Abstract   
Background: The prognosis for patients with unresectable advanced hepatocellular 
carcinoma (HCC) is poor. Miriplatin is a hydrophobic platinum compound that has a 
long retention time in lesions after transarterial chemoembolization (TACE). We 
investigated anti-tumor activity of miriplatin combined with irradiation on HCC cells, 
and its underlying mechanism of apoptosis. We also analyzed the effectiveness of 
miriplatin-TACE and radiotherapy for locally advanced HCC. 
Methods: Human HCC cell lines HepG2 and HuH-7 were treated with DPC (active 
form of miriplatin) and radiation, and synergy was evaluated using a combination index 
(CI). Apoptosis-related proteins and cell cycles were analyzed by western blotting and 
flowcytometry. We retrospectively analyzed treatment outcomes in 10 unresectable 
HCC patients with vascular/bile duct invasion treated with miriplatin-TACE and 
radiotherapy. 
Results: DPC or X-ray irradiation decreased cell viability dose-dependently. DPC plus 
irradiation decreased cell viability synergistically in both cell lines (CI<1 respectively). 
Cleaved PARP expression was induced much more strongly by DPC plus irradiation 
than by each treatment alone. Expression of p53 up-regulated modulator of apoptosis 
(PUMA) was significantly induced by the combination, and knockdown of PUMA with 
siRNA significantly decreased apoptosis in both cell lines. DPC plus irradiation caused 
sub-G1, G2/M, and S phase cell arrest in those cells. The combination of miriplatin-
TACE and radiotherapy showed a high response rate for patients with locally 
advanced HCC despite small number of patients. 
Conclusions: Miriplatin plus irradiation had synergistic anti-tumor activity on HCC 
cells through PUMA-mediated apoptosis and cell cycle arrest. This combination may 







































































































































Hepatocellular carcinoma (HCC) is the fourth-leading cause of cancer-related 
death worldwide [1]. Most patients with HCC are diagnosed at an advanced stage, 
when curative therapies, such as surgical resection and percutaneous ablation, are of 
limited utility. A majority of HCCs exhibit intrinsic resistance to many cytotoxic anti-
cancer agents and, therefore, interventional treatments such as transarterial 
chemotherapy have been applied for advanced HCC [2, 3]. Recently, the therapeutic 
efficacy of systemic treatment with sorafenib, a tyrosine kinase inhibitor, on 
unresectable HCC was reported; sorafenib significantly improved overall survival (OS) 
in patients with unresectable advanced HCC in randomized controlled phase III trials 
[4]. More recently, other tyrosine kinase inhibitors such as regorafenib and lenvatinib 
were reported to be effective for the treatment of advanced HCC [5, 6]. However, a 
serious limitation of these multi-kinase inhibitors is that they show poor efficacy for 
treating HCCs that invade the major portal vein, hepatic vein, or bile duct. Therefore, 
the prognosis for these locally advanced HCC is extremely poor [7, 8]. For example, 
Cheng and associates reported that the median survival time for cases of HCC with 
major vascular invasion was only 5.6 months despite treatment with sorafenib [9].  
With recent advances in three-dimensional radiation techniques, radiotherapy has 
become a treatment option for unresectable HCC. In particular, radiotherapy has been 
reported to be effective for treatment of portal vein and/or inferior vena cava tumor 
thrombosis in HCC [10, 11]. Moreover, transarterial chemoembolization (TACE) 
combined with radiotherapy was reported to be effective in treating HCC with portal 
vein tumor thrombus [12]. Notably, Yoon and associates reported that TACE with 
cisplatin (CDDP) combined with radiotherapy was very effective for the treatment of 


































































survival (OS) were 39.6% and 10.6 months, respectively [13]. In a randomized clinical 
trial, the same group showed that TACE with CDDP combined with radiotherapy was 
superior to sorafenib for the treatment of HCC with macroscopic vascular invasion [14]. 
However, these outcomes with respect to RR and OS of treatment with TACE with 
CDDP and radiotherapy remain unsatisfactory. In addition, CDDP has various adverse 
effects such as renal toxicity, vascular damage, and GI toxicity, and it shows poor 
tumor retention when administered as TACE [15, 16]. 
Miriplatin (cis-[1R,2R]-1,2-cyclohexanediamine- -platinum(II) 
monohydrate; Sumitomo Dainippon Pharma Co, Ltd. Osaka, Japan) is a novel 
lipophilic anti-cancer drug that can be suspended in lipiodol, a lipid lymphographic 
agent for TACE [16], and it is less toxic and has a much longer retention time in tumor 
tissues compared with CDDP. A phase II study of TACE with miriplatin and iodized oil 
showed promising efficacy for unresectable HCC with a mild toxicity profile [17]. 
Subsequent studies of TACE with miriplatin also revealed better efficacy and much 
lower toxicity for the treatment of unresectable HCC compared with other anti-cancer 
agents, despite a few contradictory reports [18, 19]. However, combination therapy 
with miriplatin and radiotherapy for HCC has not been studied to date. Therefore, in 
this study, we first investigated the anti-cancer activity and synergistic effect of 
miriplatin plus X-ray combination therapy using HCC cell lines. Since we ultimately 
observed synergistic anti-tumor activity with this combination, we next examined the 
underlying mechanism of synergistic activity, including apoptosis, using HCC cell lines. 
We also evaluated the anti-tumor activity of TACE with miriplatin combined with 
radiotherapy in HCC patients with vascular and/or bile duct invasion. 
 



































































The human HCC cell lines HepG2 and HuH-7 were purchased from American 
Tissue Culture Collection. Cells were maintained in DMEM supplemented with 10% 
fetal bovine serum (FBS).  
 
Drugs and reagents 
Miriplatin and dichloro [(1R, 2R)-1,2-cyclohexanediamine-N, N ] platinum (DPC), 
an active form of miriplatin, were provided by Sumitomo Dainippon Pharma Co, Ltd. 
DPC was dissolved in N,N-dimethylformamide (DMF) and CDDP (Sigma-Aldrich, St 
Louis, MO) was dissolved in saline.  
 
Radiation exposure 
Cells were irradiated in the medium at room temperature with an X-ray generator 
(MBR-1520R-3, Hitachi, Japan) operating at 150 kV 20 mA with a filter of 0.1 mm Cu 
and 0.5 mm Al at a dose rate of 1.0 Gy/min.  
 
Cell viability assay  
Cell viability was examined by WST-8 assay
instructions.  
 
Calculation of Combination index (CI) 
DPC or CDDP was added to the cells at a concentration of 0  10 µM, and the cells 
were irradiated with X-rays at 0  10 Gy. They were subsequently incubated at 37ºC 
for 120 h and cell viability was determined by WST-8 assay to generate a new cell 


































































according to the method of Chou and Talalay using CompuSyn software (ComboSyn, 
Paramus, NJ) [20, 21]. The CI value was plotted against the fraction of affected cells 
(Fa), which represents the percentage of growth inhibition (CI-Fa plot). Three 
independent experiments consisting of quintuplicate assays for each condition were 
performed to generate CI-Fa plots. A CI value < 1.0 indicates synergism of the 
combination.  
Western blot analysis 
 Expression of apoptosis-related proteins was analyzed by western blot analysis, 
as described previously [22]. The primary antibodies used are listed in Supplementary 
Table 1.  
 
Cell cycle analysis 
Cell cycle was analyzed using a Cell Cycle Phase Determination Kit (Cayman 
chemical, Ann Arbor, MI) a . Briefly, cells were 
seeded in 10-cm dishes and the culture medium was changed to serum-free medium 
for 24 h to facilitate cell cycle synchronization. DPC was added to the wells with or 
without irradiation. After incubation for 24 h, the DNA content of propidium iodide (PI)-
stained cell nuclei was determined using a BD FACSVerse flow cytometer (BD 
Biosciences, San Jose, CA). For analysis of DNA synthetic activity, BrdU assay was 
performed using an FITC BrdU Flow Kit (BD Biosciences), according to 
manufacture  instructions. 
 
Retrospective study of TACE with miriplatin combined with radiotherapy for 


































































We retrospectively analyzed the anti-tumor effect of TACE with miriplatin or CDDP 
combined with radiotherapy for patients with HCC between February 2012 and April 
2019 at Tokushima University Hospital. The criteria for enrollment were as follows; (i) 
unresectable HCC that macroscopically invaded the major branch of the portal vein 
(Vp1 - 3), hepatic vein (Vv1 - 3) or bile ducts (B1 - 4) in contrast-enhanced CT; and (ii)
Child Pugh classification A or B. Patients with extrahepatic metastasis or with 
invasion to the main trunk of the portal vein were excluded. A total of 10 patients in 
the miriplatin group and 15 patients in the CDDP group who satisfied the eligibility 
criteria were evaluated. This study was approved by the institutional review board of 
our university.  
We evaluated primarily the main tumor with vascular/bile duct invasion inside the 
radiation field by serial CT scans performed 3 months after the completion of TACE 
and radiotherapy, according to criteria described previously [23], as follows: complete 
response (CR), complete disappearance of tumor; partial response (PR), >30% 
reduction of tumor in the largest diameter without complete disappearance of tumor; 
progressive disease (PD), >20% extension of tumor in the largest diameter; stable 
disease (SD), neither sufficient regression to qualify for PR nor sufficient growth to 
qualify for PD. We also evaluated secondarily intrahepatic nodules outside the 
radiation field according to modified RECIST criteria [24]. OS was measured from the 
date of initial treatment to the date of death or last follow-up and assessed by the 
Kaplan Meier method. 
Detailed information on the method for clonogenic cell survival assay, apoptosis 
assay, siRNA transfection, and TACE with radiotherapy is provided in Supplementary 




































































Anti-tumor activity of DPC, CDDP and X-ray irradiation on hepatocellular 
carcinoma cell lines 
We first analyzed the anti-tumor effect of DPC, an active form of miriplatin, and 
CDDP on HepG2 and HuH-7 cells by cell viability assay. The viability of HepG2 cells 
treated with DPC or CDDP decreased in a dose-dependent manner. The IC50 values 
for DPC and CDDP were 3.66 1.45 and 6.30  1.66 µM respectively; i.e., the IC50 
of DPC was significantly lower than that of CDDP (p<0.03 t test; Fig.1A). 
Similarly, the IC50 of DPC in HuH-7 cells (0.90  0.34 µM) was significantly lower than 
that of CDDP (5.84  1.07µM, p<0.01). Thus, DPC exhibited greater anti-tumor activity 
than CDDP against both HCC cell lines. 
When HepG2 or HuH-7 cells were irradiated with X-rays at 0  10 Gy, cell viability 
decreased in a dose-dependent manner, with ED50s of 5.6 Gy and 5.2 Gy, 
respectively (Supplementary Fig.1A). 
 
Synergistic effect of DPC and X-ray irradiation on HCC cells 
To evaluate the synergistic effect of anti-tumor drug treatment and X-ray irradiation, 
we examined the viability of HepG2 and HuH-7 cells using the combination index 
method after treatment with various concentrations of DPC or CDDP in combination 
with 0  10 Gy X-ray irradiation. HepG2 and HuH-7 cell viability decreased in a dose-
dependent manner following treatment with DPC in each X-ray dose group from 0  
10 Gy (Fig.1B,C). Moreover, the viability curve for each X-ray exposure group 
gradually decreased with increasing X-ray doses. The Chou and Talalay (CI  Fa) plot 
revealed that all the in HepG2 


































































Since it is well known that synergism (CI value) at higher Fa levels is more relevant to 
the anti-cancer therapeutic effect than that at lower Fa levels [20, 25], DPC and X-ray 
irradiation were judged to have synergistic effects in both cell lines. In contrast, for 
CDDP plus X-ray irradiation only one CI value was less than 1.0 (around 0.6 of Fa) 
but the other 3 CI values (including the one at the highest Fa level) were greater than 
1.0, failing to show a downward trend of CI values with increasing Fa in both cell lines 
(Fig.1D,E). Thus, CDDP plus X-ray irradiaition was judged to have little synergy or a 
very weak synergistic effect. 
To evaluate the long-term combination effect of DPC and X-ray irradiation, we 
performed colony forming assays in HepG2 and HuH-7 cells. Representative images 
of colonies in each HepG2 treatment group are shown in Fig.2A. The number of 
colonies of HCC cells formed was lowest in cells treated with DPC plus X-ray 
irradiation as compared with all other treatment groups, although the number of 
colonies formed in cells treated with DPC or X-ray irradiation alone was also lower 
compared with control cells. Mean clonogenic survival (percentage of control cells) in 
the DPC plus X-ray irradiation group (38.3  2.1) was significantly lower than that in 
the DPC alone (51.7  3.0) and X-ray irradiation alone groups (86.8  3.7) (p<0.05 
respectively, ; Fig.2B). Mean clonogenic survival in the latter 2 groups 
was significantly lower compared with control cells (p<0.05 respectively). Similar 
results were obtained in the colony forming assay with HuH-7 cells (Fig.2C,D; p<0.05 
respectively). 
 
Apoptosis induction with DPC plus X-ray irradiation
To investigate the mechanism of the synergistic anti-tumor effect of the 


































































flow cytometry in HCC cells treated with DPC and/or X-ray irradiation, in comparison 
with CDDP and/or X-ray irradiation. When HepG2 and HuH-7 cells were treated with 
various concentrations of DPC or CDDP, the expression of cleaved PARP and 
caspase-3 was induced in a dose-dependent manner at 0  20 µM (including low 
concentrations of 0  5 µM) in both cell lines (Supplementary Fig.2A,B). Moreover, 
cleavage of PARP and caspase-3 was also induced in both cell lines in a dose-
dependent manner after treatment with X-ray irradiation alone (Supplementary Fig.1B). 
When HepG2 and HuH-7 cells were treated with DPC plus X-ray irradiation, the 
induction of cleaved PARP and caspase-3 expression was much stronger than with 
each treatment, and with CDDP plus X-ray irradiation, suggesting that the synergistic 
anti-tumor effect of DPC plus X-ray irradiation is caused by apoptosis in both cell lines 
(Fig.3A). 
In the flow cytometry analysis, the percentage of annexin V (+) in HepG2 cells 
treated with DPC plus X-ray irradiation (53.5 ± 1.7%) was significantly higher 
compared with control cells treated with vehicle alone (11.4 ± 0.4%; p<0.01 by 
) or CDDP plus X-ray irradiation (33.1 ± 2.4%; p<0.01; Fig.3B). Similarly, 
the percentage of annexin V (+) in HuH-7 cells treated with DPC plus X-ray irradiation 
(50.8 ± 1.0%) was significantly higher than that with vehicle treatment alone (13.2 ± 
1.6%, p<0.01) or CDDP plus X-ray irradiation (41.5 ± 1.5%; p<0.01; Fig.3C). 
 
Mechanism of synergistic effect of DPC and X-ray irradiation
To further investigate the mechanism of apoptosis induction by DPC and X-ray 
irradiation, we examined the expression of major apoptosis-related proteins (Bim, Bik, 
p53 up-regulated modulator of apoptosis [PUMA], Noxa, Bcl-2, Mcl-1, and Bcl-xl) in 


































































DPC alone, PUMA expression was significantly increased in a dose-dependent 
manner at 0  20 µM (including low concentrations of 0  5 µM), whereas expression 
of Bim, Bik, Noxa, Bcl-2, Mcl-1, and Bcl-xl did not change significantly (Supplementary 
Fig.2A). Conversely, PUMA expression was not changed by treatment with CDDP, 
irrespective of the concentration, suggesting that the mechanism of apoptosis 
induction by CDDP differs from that of DPC. Moreover, when HepG2 cells were treated 
with DPC plus X-ray irradiation, PUMA expression was much stronger than that of 
each treatment individually, whereas the expression of other apoptosis-related 
proteins did not change significantly (Fig.4A and Supplementary Fig.3). Quantitative 
-actin ratio) of 
HepG2 cells treated with DPC plus X-ray irradiation was significantly higher than that 
with treatment with DPC, X-ray irradiation alone, or CDDP plus X-ray irradiation, as 
well as control cells (Fig.4B). Similarly, PUMA expression was significantly increased 
in a dose-dependent manner in HuH-7 cells after treatment with DPC, whereas it did 
not change after treatment with CDDP (Supplementary Fig.2B). Moreover, PUMA 
expression of HuH-7 cells treated with DPC plus X-ray irradiation was significantly 
higher than with treatment with DPC, X-ray irradiation alone, or CDDP plus X-ray 
irradiation, as well as control cells (Fig.4C,D). These results indicate that PUMA plays 
a critical role in the induction of apoptosis by DPC and X-ray irradiation in combination. 
To investigate the mechanism of PUMA induction, we examined the expression of 
JNK, c-Jun, and CHOP expression in HepG2 and HuH-7 cells by western blotting. 
Expression of p-JNK and p-c-Jun in HepG2 cells after treatment with DPC plus X-ray 
irradiation was significantly higher compared with control cells and cells after treatment 
with CDDP plus X-ray irradiation (Fig.4E). However, expression of ER stress-related 


































































CDDP plus X-ray irradiation. Similar results were obtained in HuH-7 cells after 
treatment with DPC plus X-ray irradiation (Fig.4F). These results suggest that the 
combination of DPC plus X-ray irradiation induced PUMA expression dependent on 
the JNK signaling pathway. 
To confirm the role of PUMA in the synergistic effect of DPC and X-ray irradiation, 
we knocked down the PUMA gene in HepG2 and HuH-7 cells using siRNA and 
examined changes of apoptosis. The relative mRNA levels of PUMA in the knocked-
down cells were suppressed to 20% or less at 24  96 h after transfection with siRNA 
as compared with that of control cells (Fig.5A). The apoptotic fraction of HepG2 cells 
transfected with PUMA siRNA was 22.7 ± 3.5%, which was significantly lower than 
that of control cells (46.5 ± 3.6%) (p t test; Fig.5B). Similarly, the 
apoptotic fraction of HuH-7 cells transfected with PUMA siRNA (37.0 ± 2.6%) was 
significantly lower than that of control siRNA (45.9 ± 2.6%) (p<0.01; Fig.5C). Thus, 
knockdown of PUMA resulted in escape from apoptosis by the combination of DPC 
and X-ray irradiation in both HepG2 and HuH-7 cells. In addition, knockdown of PUMA 
decreased most strongly the cytotoxic activity of DPC plus X-ray irradiation among the 
treatments (vehicle, DPC, X-ray alone and DPC/X-ray combination), in both cell lines, 
suggesting that PUMA may play an important role in the synergistic effect of this 
combination as well as in apoptosis induction (Supplementary Table 2). 
 
Cell cycle arrest with DPC or CDDP plus X-ray irradiation
To investigate the effects of DPC or CDDP plus X-ray irradiation on the cell cycle, 
we quantified cell subpopulations in sub-G1, G0/1, S, and G2/M phases after 
treatment with DPC/CDDP and/or X-ray by flow cytometry. DPC treatment significantly 


































































cells (26.8 ± 1.7%; p ; Fig.6A), indicative of apoptosis induction. 
In contrast, X-ray irradiation significantly increased the G2/M phase population in 
HepG2 cells (30.7 ± 1.1%) compared with control cells (25.7 ± 0.7%; p<0.01), 
suggesting G2/M arrest. DPC plus X-ray irradiation significantly increased the 
apoptotic sub-G1 population (70.2 ± 0.6%; p<0.01). Similar patterns were observed in 
HepG2 cells treated with CDDP, and with CDDP plus X-ray irradiation. In contrast, 
experiments with HuH-7 cells showed that DPC significantly increased the S phase 
population (44.5 ± 5.7% vs 11.1 ± 0.6% for control; p<0.01; Fig.6B) as well as sub-G1 
population (6.7 ± 0.4% vs 4.3 ± 0.6% for control; p<0.01), and X-ray irradiation induced 
sub-G1 (8.1 ± 0.9%; p<0.01) and G2/M arrest (37.3 ± 0.5% vs 25.3 ± 0.8% for control; 
p<0.01). DPC plus X-ray irradiation significantly induced the S phase (29.1 ± 3.7%; 
p<0.01), sub-G1 (8.2 ± 0.6%; p<0.01), and G2/M phase populations (34.3 ± 1.0%; 
p<0.01) in HuH-7 cells. While CDDP increased the sub-G1 (9.7 ± 0.4%; p<0.01) and 
G0/G1 population (72.2 ± 3.0% vs 59.4 ± 0.4% for control; p<0.01), possibly leading 
to apoptosis. CDDP plus X-ray irradiation increased only the apoptotic sub-G1 
population (7.8 ± 0.8%; p<0.01). Thus, the effect of DPC on the cell cycle in HuH-7 
cells differed from that of CDDP. 
Subsequently a BrdU incorporation assay was performed to determine DNA 
synthetic activity in HepG2 and HuH-7 cells treated with DPC, X-ray irradiation, and 
both in combination. Representative data are shown in Fig.6C. Both DPC and X-ray 
irradiation significantly decreased the number of BrdU-incorporated cells in both cell 
lines. The combination of DPC plus X-ray irradiation decreased DNA synthetic activity 
most strongly (up to 0.5 - 1.0%) in both cell lines. It is expected that not only HepG2 
cells but also HuH-7 cells, which showed S phase arrest, would undergo subsequent 


































































To examine the expression of cell cycle regulators, we performed western blotting 
for cyclins A, B1, D1, and E (Fig.6D). DPC or DPC plus X-ray irradiation decreased 
cyclin D1 expression strongly in HepG2 cells, which may be associated with an 
increased sub-G1 population [27]. X-ray irradiation caused cyclin B1 accumulation in 
both cell types, consistent with G2/M arrest in those cells [28].  Moreover, DPC or DPC 
plus X-ray irradiation decreased cyclins A and E in p53 wild-type HepG2 cells, also 
consistent with previous reports [29, 30]. However, considerably weaker effects of 
CDDP plus X-ray irradiation on those cyclins were observed compared with DPC plus 
X-ray irradiation. 
 
Effect of miriplatin plus X-ray irradiation on locally advanced HCC 
To evaluate the therapeutic efficacy of miriplatin plus radiotherapy on locally 
advanced HCC, we retrospectively compared the therapeutic efficacy of miriplatin-
TACE plus radiotherapy versus CDDP-TACE plus radiotherapy for locally advanced 
HCC patients with macroscopic vascular and/or bile duct invasion. The baseline 
characteristics of the patients are summarized in Supplementary Table 3, and more 
detailed information is provided in Supplementary Table 4. No significant differences 
in characteristics including age; sex; etiology; laboratory data; liver functional reserve; 
and tumor size, number, degree of vascular/bile duct invasion, and stage were 
observed between the miriplatin and CDDP groups. Representative CT images of CR, 
PR, SD and PD for primary evaluation of the main tumor with vascular/bile duct 
invasion inside the radiation field are shown in Fig.7A-D. The HCC tumor invading the 
portal vein completely disappeared in case 9 (CR), and the tumor invading the portal 
vein shrank but still remained in case 4 (PR) after treatment with miriplatin-TACE and 


































































21 (SD), and the tumor invading the portal vein progressed in case 24 (PD) after 
treatment with CDDP-TACE and radiotherapy. In total, the overall RR in the miriplatin 
group (100% [10/10]; 8 CR and 2 PR) was significantly higher than in the CDDP group 
(53.3% [8/15]); 6 CR, 2 PR, 5 SD, 2 PD; p<0.05; Fig.7E), despite the small number of 
patients. We also evaluated secondarily intrahepatic nodules outside the radiation field 
based on modified RECIST criteria; the RR in the miriplatin group was 30% (3/10; 2 
CR, 1 PR, 2 SD, 5 PD), and was similar to that in the CDDP group (40% [6/15]; 5 CR, 
1 PR, 6 SD, 3 PD; Supplementary Table 5). OS in the miriplatin group (23.6 months; 
95% CI 6.9  33.3) was fairly higher than in the CDDP group (10.4 months; 95% CI 
4.4  21.6), although the difference was not statistically significant (p=0.16 by log rank 
test; Fig.7F). These results may suggest that the tumor with vascular/bile duct invasion 
determined the prognosis (OS) in locally advanced HCC, as described previously [7]. 
Thus, our data suggest that combination treatment with miriplatin and X-ray irradiation 
may possibly be more effective against locally advanced HCC compared with CDDP-
TACE plus radiotherapy.  
 
Discussion 
In this study, we demonstrated that miriplatin and X-ray irradiation in combination 
has a synergistic effect on HCC cells. This is the first study to have investigated the 
anti-tumor activity of miriplatin plus X-ray irradiation in vitro and in vivo. We also 
showed that this combination caused strong apoptosis mediated via PUMA expression. 
Synergistic induction of PUMA in HCC cells after treatment with the combination, and 
inhibition of apoptosis by knocking down the PUMA gene in HCC cells, indicate a 
pivotal role of PUMA in apoptosis caused by the combined treatment. Moreover, TACE 


































































in patients with unresectable HCC invading macroscopically portal/hepatic veins 
and/or bile ducts, despite a limited number of patients studied. Conversely, CDDP 
showed little synergistic effect on HCC cell lines nor did it induce PUMA to trigger 
apoptosis. 
PUMA is a key molecule for apoptosis induction by anti-tumor drugs and by 
radiotherapy. The expression of PUMA is reportedly elevated in response to DNA-
damaging stimuli through p53-dependent or p53-independent transcription. It has 
been reported that X-ray irradiation enhances PUMA expression mainly through p53-
dependent transcription activation, leading to apoptosis in oral cancer, 
nasopharyngeal cancer, and breast cancer [31]. However, no published studies have 
investigated the mechanism of apoptosis induced by miriplatin. Notably, oxaliplatin, 
whose active form, DPC, is the same as miriplatin, enhances PUMA expression in 
colorectal cancer [32]. Although it is unclear how radiation and DPC exert synergistic 
anti-tumor activity in detail, it is plausible that the combination of miriplatin and X-ray 
irradiation synergistically enhances PUMA expression, leading to strong induction of 
apoptosis in HCC cells. In addition, we used the 2 cell lines, HepG2 with p53 wild and 
HuH-7 with p53 mutant, and both lines showed similarly enhanced PUMA expression 
after treatment with DPC plus X-ray irradiation, possibly leading to induction of 
apoptosis.  
Eventually, DPC increased PUMA and cleaved PARP expression levels similarly 
in a dose-dependent manner in HepG2 and HuH-7 cells. Notably, their expression 
levels started to increase at lower DPC concentrations (0  -7 cells 


































































with the difference in IC50 of these cells for DPC, and also suggest a close association 
of PUMA with apoptosis in both cells. 
Regarding the mechanism of PUMA induction, we found enhanced p-JNK and p-
c-JUN expression but not ER stress-related protein (CHOP) expression in both cell 
lines after treatment with DPC plus X-ray irradiation (Fig.4E,F). These results suggest 
that DPC plus X-ray irradiation induced PUMA expression via the JNK signaling 
pathway, consistent with a previous report on JNK-dependent PUMA induction [33]. It 
is also assumed that induced PUMA activates Bax and Bak, leading to activation of 
the caspase cascade and ultimately to cell apoptosis. Thus, the combination of 
miriplatin and X-ray irradiation would be effective on HCC cells regardless of the status 
of p53 mutation.  In addition, the PUMA mRNA expression level was significantly lower 
in primary normal hepatocytes compared with HCC cells, and the difference in 
expression was enhanced roughly tenfold after treatment with DPC and X-ray 
irradiation (Supplementary Fig.4). These data suggest that DPC plus X-ray irradiation 
would be selectively effective against HCC cells without affecting mostly normal 
hepatocytes. 
Cisplatin, a hydrophilic agent like most other chemotherapeutic agents, is 
commonly used for TACE with or without radiation therapy in patients with HCC [34]. 
A retrospective analysis by Oguro and associates reported that TACE with miriplatin 
demonstrated a significantly lower response rate but lower rates of adverse events 
than TACE with CDDP [35]. In their report, however, the mean dose of miriplatin 
administered (50.4 mg, 64.4 µmol) was lower than that of CDDP (55.9 mg, 186.3 µmol). 
In our study, the IC50 value of DPC (miriplatin) in HCC cell lines was significantly lower 


































































activity than CDDP against HCC at quimolar doses. It remains controversial as to 
whether or not the combination of CDDP and radiation has a synergistic effect [36,37]. 
However, our results indicated that CDDP plus X-ray showed little synergy. This may 
be related to the fact that CDDP did not induce PUMA expression in cancer cells as 
revealed by our group (Supplementary Fig.2) and other investigators [39].  
In addition to analysis of apoptosis to determine the mechanism underlying the 
effect of miriplatin in combination with radiation, we also analyzed the effects of DPC 
(miriplatin) plus radiation on cell cycle arrest by flow cytometry (Fig.6). DPC alone 
induced sub-G1 arrest in HepG2 cells with wild-type p53, probably leading to p53 
dependent apoptosis. In contrast, DPC alone mainly induced S phase arrest as well 
as sub-G1 arrest in HuH-7 cells with mutant p53, which is consistent with previous 
studies showing that several anti-cancer drugs induce S phase arrest in cancer cells, 
subsequently leading to apoptosis [26]. Interestingly, our results are also compatible 
with a previous report showing that zolendronic acid induced PUMA and S phase 
arrest in cancer cells [39]. On the other hand, X-ray irradiation alone induced G2/M 
arrest in these cell lines, consistent with previous reports [28]. The combination of DPC 
plus irradiation induced both sub-G1 and S phase arrest and a much greater degree 
of G2/M arrest in HCC cells. In our study, DPC alone decreased cyclin D1 expression, 
while X-ray irradiation caused cyclin B1 accumulation, consistent with previous reports 
[28, 40]. Thus, cell cycle arrest might be associated with the synergistic effect of DPC 
and X-ray irradiation. 
In preliminary experiments, we investigated invasion capability in 5 HCC cell lines 
(HepG2, HuH-7, PLC/PRF5, HuH-1, and Hep3B) using a transwell invasive assay. 


































































PLC/PRF5, and Hep3B cells (Supplementary Fig.5A,B). Moreover, HepG2 and HuH-
7 cells were p53 wild and mutant, respectively, and thus it appears that HepG2 and 
HuH-7 cells were suitable for the current experiments. In addition, when HepG2 and 
HuH-7 cells were treated with DPC plus X-ray irradiation, invasion activity was 
significantly decreased compared with control cells after correction for viable cell 
numbers (p<0.05; Supplementary Fig.5C-E). 
Our retrospective analyses of miriplatin plus radiotherapy showed a higher 
response rates of the main tumor with vascular/bile duct invasion and longer OS times  
in locally advanced HCC than those of CDDP plus radiotherapy, despite the small 
number of patients. These values were also greater than those previously reported for 
CDDP plus radiotherapy [13, 14]. The total radiation doses in previous reports of 
CDDP plus radiotherapy ranged from 37.5  45 Gy, which is lower than the dose used 
in our study (50 Gy). The dose of CDDP in previous reports was 2 mg/kg (6.7  
whereas the dose of miriplatin in our study was 2 mg/kg (2.6  Consequently, 
it appears that the synergistic effect of miriplatin and radiotherapy in this study might 
be attributable to the high RR of the main tumor. In addition, no grade 3/4 adverse 
event was observed in the miriplatin group, although grade 3/4 adverse events were 
observed at a rate of 53.3% (8/15) in the CDDP group (Supplementary Table 6), 
consistent with previous reports showing that miriplatin is much less toxic than cisplatin 
[41].  
A limitation of this study is that the human data on miriplatin-TACE and CDDP-
TACE with radiotherapy are small sample-sized and retrospective analysis. Therefore, 
a prospective large-scale study to compare those therapies should be performed in 


































































In conclusion, our data suggest that combination treatment with miriplatin and X-
ray irradiation has a synergistic effect on HCC cells, and that this combination induces 
PUMA-mediated apoptosis as well as cell cycle arrest in HCC cells, regardless of the 
status of p53 mutation. Our results suggest that TACE with miriplatin combined with 
radiotherapy may be possibly effective for locally advanced HCC.  
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Figure 1.  
Viability of HCC cells treated with DPC and CDDP. A. HepG2 and HuH-7 cells were 
treated with DPC or CDDP for 72 h. Cell viability was then determined by WST-8 assay. 
IC50 values were calculated by non-linear regression analysis. Combination index 
analysis of DPC or CDDP combined with X-ray irradiation in HCC cells. HepG2 or 
HuH-7 cells were incubated with various concentrations of DPC (B, C) or CDDP (D, 
E) combined with X-ray exposure (0  10Gy) at a fixed ratio. After 120 h, cell viability 
was determined by WST-8 assay. The CI was calculated as described in Materials 
and Methods. A CI value <1 and >1 indicates synergistic and antagonistic effects, 
respectively. 
 
Figure 2.  
Colony formation in HCC cells after exposure to DPC and X-ray irradiation. A, C. 
Representative images of colony formation in HepG2 (A) and HuH-7 cells (C). Cells 
were treated with DPC (250 nmol/L) with or without X-ray irradiation (1 Gy), followed 
by incubation for 14 days. They were then fixed with methanol and stained with 0.4% 
crystal violet. B, D. The number of colonies in HepG2 (B) and HuH-7 cells (D) with 
greater than 50 cells was determined and expressed as a percentage of the number 
of control cells. Data represent mean ± standard deviation (SD) of triplicated 
experiments. * p  
 
Figure 3.  
Apoptosis induction in HCC cells after treatment with DPC  or CDDP (10 µM) 


































































ray irradiation alone, or DPC/CDDP + X-ray, then solubilized and subjected to western 
blot analysis for cleaved PARP and caspase-3 -actin was used as a loading control. 
B, C. Flow cytometric analysis of HepG2 (B) and HuH-7 cells (C) for annexin V-FITC 
and propidium iodide (PI) staining of cells treated with vehicle or DPC/CDDP + X-ray. 
Data represent mean ± SD of triplicate experiments. * p < 0.01 by . 
 
Figure 4.  
Expression of apoptosis-related protein, JNK signaling, and ER stress-related protein 
in HCC cells treated with DPC, CDDP, and X-ray irradiation. A, C. HepG2 (A) or HuH-
7 cells (C) were treated with vehicle, DPC (5 M), CDDP (5 M), or X-ray (5 Gy) alone, 
or DPC/CDDP + X-ray, then solubilized and subjected to western blot analysis for BH3 
only protein and Bcl- -actin was used as a loading control. B, D. Each 
of the PUMA protein bands in HepG2 (B) and HuH-7 cells (D) was specifically 
quantified and no -actin using the Image J program (National Institutes of 
Health, Bethesda, MD). **p < 0.05 vs other treatment groups by Turkey test. E, F. 
Western blot analysis was performed for JNK, p-JNK, c-Jun, p-c-Jun, and CHOP 
protein in HepG2 (E) and HuH-7 cells (F) after treatment with DPC/CDDP plus X-ray 
irradiation. 
 
Figure 5.  
Knockdown of the PUMA gene resulted in escape from apoptosis by DPC and X-ray 
irradiation in HCC cells. A. The PUMA gene in HepG2 and HuH-7 cells was knocked 
down by siRNA. The relative mRNA levels at 24, 48, 72 and 96 h were determined by 
Taqman PCR. *p < 0.01. B, C. HepG2 (B) or HuH-7 cells (C) were transfected with 


































































irradiation (5 Gy). Flow cytometric analysis for annexin V-FITC as well as for propidium 
iodide (PI) was performed. The percentages of annexin V-positive cells are presented 
as mean ± SD of triplicate experiments. **p t test. 
 
Figure 6.  
Cell cycle analysis in HCC cells after exposure to DPC or CDDP and X-ray irradiation. 
X-ray irradiation (5 Gy). HepG2 (A) and HuH-7 cells (B) were treated with vehicle, 
DPC, CDDP, X-ray irradiation alone, or DPC or CDDP plus X-ray irradiation, and cell 
cycle profile was analyzed after 24 h by flow cytometry. **; p 
C. HepG2 and HuH-7 cells were treated with vehicle, DPC or X-ray irradiation alone, 
or DPC plus X-ray irradiation, and BrdU incorporation was analyzed after 24 h by flow 
cytometry. D. HepG2 and HuH-7 cells were treated with vehicle, DPC, CDDP, X-ray 
irradiation alone, DPC plus X-ray irradiation, or CDDP plus X-ray irradiation, and cyclin 
expression was analyzed after 24 h by western blotting. 
 
Figure 7.  
Response and survival of HCC with vascular/bile duct invasion to transarterial 
chemoembolization (TACE) with miriplatin or TACE with CDDP combined with 
radiotherapy. Representative CT images of CR, PR, SD, and PD before and after 
treatment. A. An abdominal CT scan during the portal-venous phase in case 9 with 
HCC invading the portal vein. The tumor and portal invasion completely disappeared 
(CR) after miriplatin-TACE with radiotherapy. B. An abdominal CT scan during the 
portal-venous phase in case 4 with tumor invading the portal vein. The tumor invading 


































































C. The tumor invading portal vein showed little change (SD) in case 21 after CDDP-
TACE with radiotherapy. D. The size of tumor invading portal vein enlarged (PD) in 
case 24 after CDDP-TACE with radiotherapy. E. Summary of response in miriplatin 
and CDDP groups. F. Overall survival of patients in the miriplatin and CDDP groups 




Supplementary Figure 1.  
Anti-tumor effect of X-ray irradiation on HCC cells. A. HepG2 and HuH-7 cells were 
irradiated with X-rays at 0, 2.5, 5, 7.5 and 10 Gy. After 5 days, cell viability was 
analyzed by WST-8 assay. ED50 values were calculated by non-linear regression 
analysis. B. HCC cells were irradiated with X-rays at each dose, then solubilized after 
5 days and subjected to western blot analysis for PARP. 
 
Supplementary Figure 2.  
Expression of apoptosis-related protein in HCC cells after treatment with DPC or 
CDDP. HepG2 (A) and HuH-7cells (B) were treated with DPC or CDDP at 0 - 20 µM 
for 48 h, then solubilized and subjected to western blot analysis for BH3 only protein 
and Bcl-2 family prot -actin was used as a loading control. 
 
Supplementary Figure 3.  
Quantitation of apoptosis-related protein expression in HepG2 and HuH-7 cells. The 


































































HuH-7 cells (B) detected by western blot analysis were specifically quantitated and 
-actin using the Image J program. 
 
Supplementary Figure 4.  
The expression of PUMA mRNA in normal hepatocytes and HepG2 cells after 
treatment with DPC, X-ray irradiation, and DPC plus X-ray irradiation. Normal 
hepatocytes or HepG2 cells were treated with DPC plus X-ray irradiation, and PUMA 
mRNA expression levels were determined by Taqman PCR. N.S., not significant. *p < 
0.01 by Turkey  test. **The relative mRNA level of PUMA in normal hepatocytes was 
significantly lower than in HepG2 cells. p t test. 
 
Supplementary Figure 5.  
Invasion capability of HCC cells treated with DPC and X-ray irradiation. A. The 
invasion capability of 5 HCC cell lines was determined by transwell assay. A 
representative image of each cell line is shown. B. Five randomly selected fields were 
imaged and the number of invading cells was counted as described in Supplementary 
information. **p < 0.01 by Turkey  test. C. HepG2 and HuH-7 cells were treated with 
vehicle alone or DPC plus X-ray irradiation, cultured for 48 h, and invasion assay was 
performed. Representative images of HepG2 and HuH-7 cells are shown. D,E. The 
mean numbers of invading cells in HepG2 and HuH-7 cells are shown. **p < 0.01 by 
t test. 
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